Home Cart Sign in  
Chemical Structure| 1050477-31-0 Chemical Structure| 1050477-31-0

Structure of Finerenone
CAS No.: 1050477-31-0

Chemical Structure| 1050477-31-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Finerenone is a novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonist with IC50 value of 18nM.

Synonyms: BAY 94-8862; FIN

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Finerenone

CAS No. :1050477-31-0
Formula : C21H22N4O3
M.W : 378.42
SMILES Code : O=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@@H]1C3=CC=C(C#N)C=C3OC)N
Synonyms :
BAY 94-8862; FIN
MDL No. :MFCD29047135
InChI Key :BTBHLEZXCOBLCY-QGZVFWFLSA-N
Pubchem ID :60150535

Safety of Finerenone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NRK-49F fibroblasts 5µmol/L, 50µmol/L, 100µmol/L 24 hours To investigate the effect of finerenone on aldosterone-induced Ccn2 expression in NRK-49F cells. Results showed finerenone dose-dependently prevented aldosterone-induced increase in Ccn2 mRNA levels. PMC11587750
Vascular smooth muscle cells (VSMCs) 5µmol/L 24 hours To evaluate the effect of finerenone on aldosterone-induced Glp1r expression in VSMCs. Results showed finerenone blocked the downregulation of Glp1r by aldosterone. PMC11587750
Human kidney proximal tubular epithelial cells (HK-2 cells) 5 mM 24 hours FIN reduced oxidative stress, mitochondrial fragmentation, and apoptosis while restoring mitophagy via the PI3K/Akt/eNOS signaling pathway. PMC10661120
RAW 264.7 macrophages 5 mM 72 hours To investigate the effect of finerenone on the expression of C5aR1 and Gnαi2 in macrophages under high glucose conditions. Results showed that finerenone significantly downregulated the expression of C5aR1 and Gnαi2 and reduced the secretion of inflammatory chemokines CXCL15 and CCL2. PMC11898422

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J male mice High-fat diet-induced obesity model Dietary administration 100 ppm (i.e. 0.1 g Fine/kg of diet) For 12 weeks To compare the metabolic and adipose tissue-specific effects of finerenone and spironolactone in a mouse model of high-fat diet-induced obesity. Results showed that finerenone increased recruitment of brown adipose tissue (iBAT) and improved insulin resistance, whereas spironolactone did not have these effects. PMC8285041
C57BL/6J mice High fat diet combined with streptozotocin-induced diabetes model Dietary administration 100 mg/kg diet For 2 weeks To evaluate the effect of finerenone on the expression of Glp1r, Gipr, and Gcgr in the heart and kidneys of diabetic mice. Results showed finerenone attenuated the downregulation of Glp1r and Gcgr in the kidneys and Gipr in the heart of diabetic mice, and improved cardiac diastolic function (E/A ratio) and myocyte size. PMC11587750
C57BL/6J male mice High-fat diet/streptozotocin-induced type 2 diabetic mouse model Oral 3 mg/kg/d Once daily for 12 weeks FIN attenuated diabetic tubulopathy and improved renal function and mitochondrial function via the PI3K/Akt/eNOS signaling pathway. PMC10661120
Mice Diabetic nephropathy model Oral 10 mg/kg/day Once daily for 10 weeks To evaluate the renal improvement of finerenone in diabetic nephropathy mice. Results showed that finerenone significantly reduced the urine albumin-to-creatinine ratio (uACR), improved tubulointerstitial injury, and inhibited the over-activation of the C5a-C5aR1 axis. PMC11898422
Transgenic (mRen-2)27 rats Diabetic and hypertensive model Oral gavage 10 mg/kg/day Once daily for 12 weeks To evaluate the effects of finerenone on retinal vascular pathology and inflammation in diabetic and hypertensive rats. Results showed that finerenone reduced retinal vascular leakage, VEGF expression, and inflammatory responses. PMC9917037
Mice Ovariectomized mouse model Mixed in food 1 mg/kg/day Daily administration for 1 month Finerenone improved left ventricular diastolic function, coronary endothelial function, exercise capacity, and metabolic parameters in ovariectomized mice. PMC8120350
Mice Duchenne muscular dystrophy (DMD) model Oral Approximately 3 mg/kg/day Once daily for 16 weeks To evaluate the efficacy of finerenone as a monotherapy in improving cardiac and skeletal muscle function in a DMD model. Results showed significant improvements in cardiac strain rate and skeletal muscle grip strength, and reduced muscle damage. PMC7754779

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06727409 Patients with Type 2 Diabetes PHASE4 RECRUITING 2026-12-31 3M, Diabetes and Endocrine Res... More >>earch Center, Hong Kong, Hong Kong Less <<
NCT06381323 Primary Aldosteronism|Finereno... More >>ne|Mineralocorticoid Receptor Antagonist Less << PHASE4 RECRUITING 2027-04-01 Department of Endocrinology, D... More >>rum Tower Hospital affiliated to Nanjing University Medical School, Nanjing, Jiangsu, 210008, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.21mL

2.64mL

1.32mL

26.43mL

5.29mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories